Why This Heart Drug Could Be a $5B Blockbuster for Novartis
Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year. Source: BioSpace
Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year. Source: BioSpace
The latest funding round gives XtalPi $20M in the bank, which the company said makes it "one of the top-funded AI-powered biotechs." Source: BioSpace
This acquisition strategy is part of its two-pronged approach to growth, along with internal R&D. Source: BioSpace
Could Cara be the answer for investors itching to make $1 million? Source: BioSpace
But for now, the world’s biggest healthcare company isn’t providing many details on how it may use the extra money from lower tax rates. Source: BioSpace
The company expects the new facility will include commercial manufacturing capabilities in 18 to 24 months. Source: BioSpace
The companies will collaborate on research to study a previously unrecognized role for peripheral immune cells in the pathology of central nervous system disorders. Source: BioSpace
The year is already off to a good start with mergers and acquisitions in the biopharma industry. Source: BioSpace
Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types. Source: BioSpace
Hannestad will be responsible for Alkahest's clinical programs in Alzheimer's and Parkinson's Disease. Source: BioSpace